NU 206

Drug Profile

NU 206

Alternative Names: NU206; R-Spondin-1; RSpo-1

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kirin Pharma Company; Nuvelo
  • Developer ARCA biopharma Inc; Kyowa Hakko Kirin; Nuvelo
  • Class Growth factors; Proteins
  • Mechanism of Action Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bone disorders; Inflammatory bowel diseases; Mucositis; Rheumatoid arthritis; Stomatitis; Wounds

Most Recent Events

  • 04 Oct 2012 Discontinued - Phase-I for Bone disorders in Australia (IV)
  • 04 Oct 2012 Discontinued - Phase-I for Mucositis in Australia (IV)
  • 04 Oct 2012 Discontinued - Phase-I for Wounds in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top